Navigation Links
Results of the BRIDGE trial reported at TCT 2011
Date:11/9/2011

SAN FRANCISCO, CA November 9, 2011 Data from the BRIDGE clinical trial demonstrate that intravenous use of the drug cangrelor was effective at maintaining platelet inhibition in patients on thienopyridines who required bypass surgery. Trial results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation.

Thienopyridines are anti-platelet medications that work to prevent blood clotting and improve circulation. Though they are among the most widely prescribed medications, their use can be complicated by the unanticipated need for surgery. Despite increased risk of thrombosis, guidelines recommend discontinuing thienopyridines 5 7 days prior to surgery to minimize bleeding.

In the BRIDGE trial, researchers sought to determine whether the investigational drug cangrelor could be used as a "bridge" between discontinuing thienopyridines and surgery.

BRIDGE is a prospective, randomized double-blind, placebo-controlled, multicenter trial in 210 patients with acute coronary syndrome (ACS) or treated with a coronary stent on a thienopyridine awaiting coronary artery bypass grafting (CABG) to receive either cangrelor or placebo after an initial open-label, dose-finding phase. After thienopyridines were stopped, patients were administered cangrelor or a placebo for at least 48 hours, which was then discontinued 1 6 hours prior to surgery.

The primary efficacy endpoint of the trial was platelet reactivity (measured in P2Y12 Reaction Units [PRU]), assessed daily with the VerifyNowTM P2Y12 assay. The main safety endpoint was excessive CABG-related bleeding.

The dose of cangrelor determined in the open-label stage was 0.75 g/kg/min. In the randomized phase, a greater proportion of patients treated with cangrelor had low levels of platelet reactivity throughout the entire treatment period compared with placebo (primary endpoint, PRU<240: 98.8% vs. 19.0%; odds ratio: 353, 95% confidence interval: 45.6-2728, p<0.001). Excessive CABG-related bleeding occurred in 11.8% vs. 10.4% in the cangrelor and placebo groups, respectively (p=0.76). There were no significant differences in major bleeding prior to CABG, although minor bleeding was numerically higher with cangrelor.

"Results of the BRIDGE trial indicate that in patients on thienopyridines who undergo cardiac surgery, intravenous cangrelor provides effective maintenance of platelet inhibition with no apparent increase in major bleeding, despite numerically higher rates of minor bleeding prior to surgery, which however were mostly attributed to ecchymosis at the site of venipuncture. Larger patient samples are needed to more definitively assert the safety and effectiveness of cangrelor bridging therapy to surgery," said Dominick J. Angiolillo, MD, PhD, the lead investigator of the trial. Dr. Angiolillo is an Associate Professor of Medicine and Director of Cardiovascular Research at the University of Florida College of Medicine in Jacksonville, Florida.


'/>"/>

Contact: Judy Romero
jromero@crf.org
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. First results of Angiomax (bivalirudin) vs. heparin in transcatheter aortic valve interventions
2. Osteoarthritis results from inflammatory processes, not just wear and tear, Stanford study suggests
3. E-counselling shows dramatic results in lowering blood pressure
4. Less Frequent Mammograms May Lower False-Positive Results
5. Mayo Clinic wins grant to study ethics of sharing genetic test results with relatives
6. TGen/Virginia G. Piper Cancer Center publish results of new drug for pancreatic cancer patients
7. Virtual fly-through bronchoscopy yields real results
8. Mixed Results Seen With Off-Label Use of Antipsychotics
9. Company stock prices before public announcements of oncology trial results
10. Check Plastic Surgeons Credentials or Risk Tragic Results, Experts Warn
11. Parents anxiety about newborn screening results does not lead to increased health care use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Radabaugh & Associates, a ... communities in North-Central West Virginia, is embarking on a cooperative charity effort with ... area. , The Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for ...
(Date:8/18/2017)... TX (PRWEB) , ... August 18, 2017 , ... ... management and financial planning firm that serves residential and commercial clients in the ... charity drive to raise community support for the fight against cancer. , Founded ...
(Date:8/18/2017)... ... August 18, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh ... the veil on false teachings pertaining to the mother of the Savior whom the world ... a far different picture of the role of this historical woman. , “The world ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Our Mountains to Climb: ... of a couple that grew stronger together through the faith they shared to overcome ... Trials” is the creation of published author, Barbara J. Corcoran, a retired teacher and ...
(Date:8/18/2017)... ... ... Super Heroes of the Bible”: a gripping and potent text that uses the ... may have on the reader’s life. “Depressed: Super Heroes of the Bible” is the ... of her time enjoying nature and her family in West Virginia. , Linhart ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)...  Axium Pharmaceuticals Inc., the creator of the drug Truveta ... stages of an IPO. The United States ... cost of a prescription epilepsy drug being $450.00-$1200.00 for a one month ... AXIUM PHARMACEUTICALS, INC ... Another staggering figure is the fact that Americans spent $42 billion on ...
(Date:8/15/2017)... 2017  AOTI Inc. announced today that its fully owned ... opened a New York City Office in Yonkers, New ... Topical Wound Oxygen (TWO 2 ) homecare therapy. This new East ... Health Care (ACHC) under the company,s DMEPOS accreditation for Home/Durable Medical ... Advanced Oxygen ...
(Date:8/11/2017)... Aug. 11, 2017 DarioHealth Corp. (NASDAQ: DRIO), ... and big data solutions, today announced that it will ... 14 and host a conference call at 9:00am ET. ... and financial results and its strategy and outlook for ... by Erez Raphael , Chief Executive Officer, and ...
Breaking Medicine Technology: